Shattuck Labs Announces Preclinical Proof of Concept Study on Gamma Delta T Cell Engager, GADLEN™, Platform at SITC 2020

AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of preclinical data from its Gamma Delta T Cell Engager, or GADLEN™, platform. The presentation, titled “In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells”, will be presented by Suresh de Silva, Ph.D., VP of Product Development at Shattuck, at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020. The GADLEN platform is a novel class of bi-functional fusion proteins that are T cell engager molecules targeting gamma delta T cells to kill tumor cells expressing specific tumor antigens.

The presentation demonstrates that a mouse butyrophilin heterodimer can activate mouse gamma delta T cells in vitro and in vivo to target the killing of lymphoma cells expressing the CD19 antigen. Additionally, the human heterodimeric fusion protein BTN2A1/3A1-Fc-CD19scFv, has also demonstrated its ability to bind both the V9V2 on gamma delta T cells and CD19 on lymphoma cells.

“In vivo manipulation of gamma delta T cells holds great promise for treating cancers that are resistant or refractory to immune checkpoint blockade, however technical challenges have hindered this therapeutic goal until recently,” said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. “These data indicate that dual-sided fusion proteins comprising butyrophilin heterodimers are well-suited to engage gamma delta T cells in vivo, stimulate those cells to proliferate and specifically kill CD19 positive tumor cells. While CD19 is a useful model antigen for feasibility, we believe these data pave the way to develop GADLEN compounds for a range of tumors and tumor antigens.”

The poster presentation will be available under the section of the Company’s website.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit:

Forward Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, our expectations regarding results from our preclinical studies and our expectations regarding our GADLEN platform, its promise for treating cancer and autoimmune diseases and its potential to address checkpoint refractory patients and other areas of high unmet needs. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “promises,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the “SEC”)), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; and other risks and uncertainties identified in our Registration Statement on Form S-1 (File No. 333-248918), as amended, filed with the U.S. Securities and Exchange Commission. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Conor Richardson

Director of Finance

Shattuck Labs, Inc.

Media Contact:

Stephanie Ascher

Managing Director

Stern Investor Relations, Inc.